285 related articles for article (PubMed ID: 16714186)
61. Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man.
Pedersen GK; Sjursen H; Nøstbakken JK; Jul-Larsen Å; Hoschler K; Cox RJ
Hum Vaccin Immunother; 2014; 10(8):2408-16. PubMed ID: 25424948
[TBL] [Abstract][Full Text] [Related]
62. Immunogenicity and Safety of Pandemic Influenza H5N1 Vaccines in Healthy Adults through Meta-Analysis.
Guo Q; Liu Z; Gao J; Zhou J; Hu W; Cun Y; Li W; Liao G
Cell Physiol Biochem; 2016; 40(5):921-932. PubMed ID: 27941323
[TBL] [Abstract][Full Text] [Related]
63. A/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel®].
Plosker GL
Drugs; 2012 Jul; 72(11):1543-57. PubMed ID: 22788239
[TBL] [Abstract][Full Text] [Related]
64. Characterization of a whole, inactivated influenza (H5N1) vaccine.
Tada Y
Influenza Other Respir Viruses; 2008 Nov; 2(6):261-6. PubMed ID: 19453403
[TBL] [Abstract][Full Text] [Related]
65. [Comparative clinical trial of vaccines against avian influenza].
Zverev VV; Katlinskiĭ AV; Kostinov MP; Zhirova SN; Erofeeva MK; Stukova MA; Korovkin SA; Mel'nikov SIa; Semchenko AV; Mironov AN
Zh Mikrobiol Epidemiol Immunobiol; 2007; (3):10-6. PubMed ID: 17672124
[TBL] [Abstract][Full Text] [Related]
66. A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development.
Vajo Z; Wood J; Kosa L; Szilvasy I; Paragh G; Pauliny Z; Bartha K; Visontay I; Kis A; Jankovics I
J Virol; 2010 Feb; 84(3):1237-42. PubMed ID: 19906909
[TBL] [Abstract][Full Text] [Related]
67. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.
Rümke HC; Bayas JM; de Juanes JR; Caso C; Richardus JH; Campins M; Rombo L; Duval X; Romanenko V; Schwarz TF; Fassakhov R; Abad-Santos F; von Sonnenburg F; Dramé M; Sänger R; Ballou WR
Vaccine; 2008 May; 26(19):2378-88. PubMed ID: 18407382
[TBL] [Abstract][Full Text] [Related]
68. A/H5N1 prepandemic influenza vaccine (Vepacel®): a guide to its use.
Keating GM; Plosker GL; Lyseng-Williamson KA
BioDrugs; 2012 Dec; 26(6):425-30. PubMed ID: 23106407
[TBL] [Abstract][Full Text] [Related]
69. Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine.
Beigel JH; Voell J; Huang CY; Burbelo PD; Lane HC
J Infect Dis; 2009 Aug; 200(4):501-9. PubMed ID: 19569973
[TBL] [Abstract][Full Text] [Related]
70. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial.
Stephenson I; Nicholson KG; Glück R; Mischler R; Newman RW; Palache AM; Verlander NQ; Warburton F; Wood JM; Zambon MC
Lancet; 2003 Dec; 362(9400):1959-66. PubMed ID: 14683655
[TBL] [Abstract][Full Text] [Related]
71. Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial.
Heijmans S; De Meulemeester M; Reynders P; Giet D; Demanet E; Devresse PY; Icardi G; Dramé M; Roman F; Gillard P
J Infect Dis; 2011 Apr; 203(8):1054-62. PubMed ID: 21450995
[TBL] [Abstract][Full Text] [Related]
72. Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains.
Höschler K; Gopal R; Andrews N; Saville M; Pepin S; Wood J; Zambon MC
Influenza Other Respir Viruses; 2007; 1(5-6):199-206. PubMed ID: 19453427
[TBL] [Abstract][Full Text] [Related]
73. Safety and immunogenicity of Sinovac's prototype pandemic influenza H5N1 vaccines: a review on clinical trials.
Qiu YZ; Yin WD
Influenza Other Respir Viruses; 2008 Nov; 2(6):237-42. PubMed ID: 19453400
[TBL] [Abstract][Full Text] [Related]
74. Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice.
Huang MH; Lin SC; Hsiao CH; Chao HJ; Yang HR; Liao CC; Chuang PW; Wu HP; Huang CY; Leng CH; Liu SJ; Chen HW; Chou AH; Hu AY; Chong P
PLoS One; 2010 Aug; 5(8):e12279. PubMed ID: 20808862
[TBL] [Abstract][Full Text] [Related]
75. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant.
Stavaru C; Onu A; Lupulescu E; Tucureanu C; Rasid O; Vlase E; Coman C; Caras I; Ghiorghisor A; Berbecila L; Tofan V; Bowen RA; Marlenee N; Hartwig A; Bielefeldt-Ohmann H; Baldwin SL; Van Hoeven N; Vedvick TS; Huynh C; O'Hara MK; Noah DL; Fox CB
Hum Vaccin Immunother; 2016 Apr; 12(4):1009-26. PubMed ID: 26618392
[TBL] [Abstract][Full Text] [Related]
76. Immunogenicity of H5N1 influenza vaccines in elderly adults: a systematic review and meta-analysis.
Zhang K; Wu X; Shi Y; Gou X; Huang J
Hum Vaccin Immunother; 2021 Feb; 17(2):475-484. PubMed ID: 32692606
[TBL] [Abstract][Full Text] [Related]
77. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling.
Geeraedts F; Goutagny N; Hornung V; Severa M; de Haan A; Pool J; Wilschut J; Fitzgerald KA; Huckriede A
PLoS Pathog; 2008 Aug; 4(8):e1000138. PubMed ID: 18769719
[TBL] [Abstract][Full Text] [Related]
78. Safety and immunogenicity of prepandemic H5N1 influenza vaccines: a systematic review of the literature.
Prieto-Lara E; Llanos-Méndez A
Vaccine; 2010 Jun; 28(26):4328-34. PubMed ID: 20403350
[TBL] [Abstract][Full Text] [Related]
79. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure.
Noah DL; Hill H; Hines D; White EL; Wolff MC
Clin Vaccine Immunol; 2009 Apr; 16(4):558-66. PubMed ID: 19225073
[TBL] [Abstract][Full Text] [Related]
80. Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures.
Geeraedts F; Saluja V; ter Veer W; Amorij JP; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
AAPS J; 2010 Jun; 12(2):215-22. PubMed ID: 20195930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
